Prostate cancer: Diabetes and prostate cancer - An open debate

Nature Reviews Urology

Volumn 10, Issue 1, 2013, Pages 12-14

  De Nunzio, Cosimo ^a   Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SOMATOMEDIN C;

AGE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; FAMILY HISTORY; GEOGRAPHICAL VARIATION (SPECIES); GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; IN VITRO STUDY; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RACE; RISK REDUCTION;

AGE FACTORS; AGED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84871921115     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.239     Document Type: Article

References (10)

1. Center, M. M. et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079-1092 (2012).
2. De Nunzio, C., Aronson, W., Freedland, S. J., Giovannucci, E. & Parsons, J. K. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 61, 560-570 (2012).
3. Bansal, D., Bhansali, A., Kapil, G., Untela, K. & Titani, P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2012.40.
4. Hitron, A., Adams, V., Talbert, J. & Steinke, D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol. 36, e243-e250 (2012).
5. Kasper, J. S. & Giovannucci, E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 2056-2062 (2006).
6. Hara, N. Prostate carcinogenesis with diabetes and androgen-deprivation- therapy-related diabetes: an update. Exp. Diabetes Res. 2012, 801610.
7. De Nunzio, C. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 60, 106-117 (2011).
8. Jalving, M. et al. Metformin: taking away the candy for cancer?. Eur. J. Cancer 46, 2369-2380 (2010).
9. Wright, J. L. & Stanford, J. L. Metformin use and prostate cancer in Caucasian men: results from a population based case control study. Cancer Causes Control 20, 1617-1622 (2009).
10. Soranna, D. et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17, 813-822 (2012).